Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

03/12/2015 - 4 minutes

Neovacs autoimmune diseases

BIO-Europe 2015 was a good opportunity for us to meet people who are playing a key role in the Biotech industry. I had the opportunity to meet Miguel Sieler, CEO of Neovacs, a company that can potentially be the first to develop a therapeutic vaccine for lupus patients!

Neovacs is a French biotechnology company developing a new approach: an active immunotherapy. In some autoimmune diseases like Lupus, Crohn’s disease or rheumatoid arthritis, the cytokines that normally activate our immune system are overproduced. This overproduction can lead the immune system to attack healthy tissues and trigger dangerous inflammations. Neovacs’ active immunotherapy uses the patient’s own immune system to regulate inappropriate cytokine overproduction that may occur in autoimmune diseases or even some cancers.

As Miguel Sieler explained to me, “Neovacs’ technology, called Kinoid, is obtained by chemically linking the cytokine of interest to a foreign carrier protein”. When injected into the patient, the B-lymphocytes of the immune system of the patient will develop polyclonal antibodies against the cytokine presented on the carrier protein.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member